Patient demographics and EOL outcomes, stratified by type of hematologic malignancy
| Variable . | All patients (N = 34 088) . | Leukemia (n = 8859) . | Myeloma (n = 6750) . | MDS/MPN (n = 4941) . | Lymphoma (n = 13 538) . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median age at time of death (IQR), y | 79 (73-85) | 79 (73-85) | 77 (72-84) | 81 (75-87) | 79 (74-86) | |||||
| Sex, n (%) | ||||||||||
| Females | 15 740 (46.2) | 3918 (44.2) | 3179 (47.1) | 2043 (41.3) | 6 600 (48.8) | |||||
| Males | 18 348 (53.8) | 4941 (55.8) | 3571 (52.9) | 2898 (58.7) | 6 938 (51.2) | |||||
| Race/ethnicity, n (%) | ||||||||||
| White non-Hispanic | 27 374 (80.3) | 7282 (82.2) | 4943 (73.2) | 4157 (84.1) | 10 992 (81.2) | |||||
| White Hispanic | 2 260 (6.6) | 510 (5.8) | 458 (6.8) | 242 (4.9) | 1 050 (7.8) | |||||
| African American | 2 464 (7.2) | 564 (6.4) | 991 (14.7) | 257 (5.2) | 652 (4.8) | |||||
| Asian/other | 1 990 (5.8) | 503 (5.7) | 358 (5.3) | 285 (5.8) | 844 (6.2) | |||||
| Any prior chemotherapy,* n (%) | ||||||||||
| No | 7 168 (35.7) | 1891 (36.6) | 1039 (25.0) | 1238 (43.8) | 3 000 (37.9) | |||||
| Yes | 12 887 (64.3) | 3271 (63.4) | 3116 (75.0) | 1589 (56.2) | 4 911 (62.1) | |||||
| EOL outcomes, n (%) | ||||||||||
| Hospice use | 19 267 (56.5) | 4711 (53.2) | 4011 (59.4) | 2795 (56.6) | 7 750 (57.2) | |||||
| ≤3 d on hospice | 5 139 (26.7) | 1373 (29.1) | 1022 (25.5) | 819 (29.3) | 1 925 (24.8) | |||||
| Inpatient death | 11 254 (33.0) | 3193 (36.0) | 1998 (29.6) | 1628 (32.9) | 4 435 (32.8) | |||||
| ICU admission within 30 d | 12 535 (36.8) | 3345 (37.8) | 2401 (35.6) | 1752 (35.5) | 5 037 (37.2) | |||||
| Chemotherapy within 14 d | 2 663 (13.3) | 871 (16.9) | 534 (12.9) | 280 (9.9) | 978 (12.4) | |||||
| Hospice LOS, median (IQR), d | 9 (3-27) | 9 (3-24) | 9 (3-27) | 9 (3-25) | 10 (4-29) |
| Variable . | All patients (N = 34 088) . | Leukemia (n = 8859) . | Myeloma (n = 6750) . | MDS/MPN (n = 4941) . | Lymphoma (n = 13 538) . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median age at time of death (IQR), y | 79 (73-85) | 79 (73-85) | 77 (72-84) | 81 (75-87) | 79 (74-86) | |||||
| Sex, n (%) | ||||||||||
| Females | 15 740 (46.2) | 3918 (44.2) | 3179 (47.1) | 2043 (41.3) | 6 600 (48.8) | |||||
| Males | 18 348 (53.8) | 4941 (55.8) | 3571 (52.9) | 2898 (58.7) | 6 938 (51.2) | |||||
| Race/ethnicity, n (%) | ||||||||||
| White non-Hispanic | 27 374 (80.3) | 7282 (82.2) | 4943 (73.2) | 4157 (84.1) | 10 992 (81.2) | |||||
| White Hispanic | 2 260 (6.6) | 510 (5.8) | 458 (6.8) | 242 (4.9) | 1 050 (7.8) | |||||
| African American | 2 464 (7.2) | 564 (6.4) | 991 (14.7) | 257 (5.2) | 652 (4.8) | |||||
| Asian/other | 1 990 (5.8) | 503 (5.7) | 358 (5.3) | 285 (5.8) | 844 (6.2) | |||||
| Any prior chemotherapy,* n (%) | ||||||||||
| No | 7 168 (35.7) | 1891 (36.6) | 1039 (25.0) | 1238 (43.8) | 3 000 (37.9) | |||||
| Yes | 12 887 (64.3) | 3271 (63.4) | 3116 (75.0) | 1589 (56.2) | 4 911 (62.1) | |||||
| EOL outcomes, n (%) | ||||||||||
| Hospice use | 19 267 (56.5) | 4711 (53.2) | 4011 (59.4) | 2795 (56.6) | 7 750 (57.2) | |||||
| ≤3 d on hospice | 5 139 (26.7) | 1373 (29.1) | 1022 (25.5) | 819 (29.3) | 1 925 (24.8) | |||||
| Inpatient death | 11 254 (33.0) | 3193 (36.0) | 1998 (29.6) | 1628 (32.9) | 4 435 (32.8) | |||||
| ICU admission within 30 d | 12 535 (36.8) | 3345 (37.8) | 2401 (35.6) | 1752 (35.5) | 5 037 (37.2) | |||||
| Chemotherapy within 14 d | 2 663 (13.3) | 871 (16.9) | 534 (12.9) | 280 (9.9) | 978 (12.4) | |||||
| Hospice LOS, median (IQR), d | 9 (3-27) | 9 (3-24) | 9 (3-27) | 9 (3-25) | 10 (4-29) |
Within 1 year prior to death; ascertained only for beneficiaries enrolled in Medicare Part D.